Altay Therapeutics YC 지원서

Winter 2020Active

Altay Therapeutics은(는) Winter 2020 배치에서 Healthcare 회사로 Y Combinator를 거쳤습니다. 아래에는 회사의 사업 내용, 창립자, 그리고 실제 YC 양식에 맞춰 재구성한 YC 지원서가 있습니다.

YC 배치: Winter 2020
산업: HealthcareTherapeutics
팀 규모: 6
상태: Active
출시됨: 2020

창업자

Ali OzesFounder
Osman OzesFounder

Altay Therapeutics의 사업 내용

Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer. Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue. With a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affects over 20 million Americans and represents a market size of over $30 billion. We know we are well positioned for success because we have shown excellent pre-clinical mouse data in several liver fibrosis models using our novel small molecule. We demonstrate a reduction in fibrosis with our drug, but more significantly, we show a reversal in fibrotic tissue back to normal tissue. With our current developmental strategy, we hope to have a clinic-ready compound by the end of 2021 and be in phase I clinical trials by mid of 2022.

Altay Therapeutics의 YC 지원서, 재구성됨

Y Combinator 지원

Altay Therapeutics, Winter 2020 기수. 공개 데이터를 기반으로 작성된 실제 지원 질문.

Founders2
Company7
Progress7
Idea4
Equity3
Curious2
Batch Preference1

Company

Company name

Altay Therapeutics

Describe what your company does in 50 characters or less.

Small molecule therapies for liver disease

What is your company going to make? Please describe your product and what it does or will do.

We develop small molecule drugs that target transcription pathways to treat chronic liver diseases like fibrosis and cancer. Our lead compound has shown in mouse models not just reduction but reversal of liver fibrosis, aiming for a clinic-ready drug by end of 2021 and phase I trials mid-2022.

Where do you live now, and where would the company be based after YC?

We live and work in San Francisco and South San Francisco, CA, which will remain our base after YC.

Explain your decision regarding location.

We chose to base the company in San Francisco because that's where the biotech innovation ecosystem and our team are. It keeps us close to partners, investors, and talent relevant to small molecule therapeutic development.

전체 지원서에서 21개의 추가 답변

Founders, Progress, Idea, Equity, Curious, Batch Preference는 전체 버전에 있습니다. 무료 계정을 만들어 YC Insights에서 모든 YC 배치 옆에 열어보세요.

전체 지원 보기

자주 묻는 질문

Altay Therapeutics의 실제 YC 지원서인가요?

아닙니다. Y Combinator는 제출된 지원서를 비공개로 유지합니다. 이것은 재구성된 것입니다. 실제 YC 양식 질문에 Altay Therapeutics의 공개 데이터(출시 노트, 창업자 배경, 제품 설명)를 기반으로 답변했습니다. Altay Therapeutics과 같은 회사가 YC에 어떻게 자신을 소개하는지 보여주며, 그들이 제출한 텍스트는 아닙니다.